Global Transcatheter Aortic Valve Implantation (TAVI) Market: Industry Analysis & Outlook (2018-2022)
Transcatheter aortic valve implantation (TAVI) is a relatively new technology in the field of medical science. It is a minimally invasive surgery of replacing heart valve without undergoing the conventional by-pass surgery. It has emerged as one of the most feasible alternatives to conventional surgical aortic valve replacement. Transcatheter aortic valve implantation is also sometimes called as Transcatheter Aortic Valve Replacement (TAVR). The transcatheter aortic valve replacement market has gained popularity as a treatment option for those who are too weak to undergo surgery or are at high risk.
There are multiple approaches for TAVI procedure which includes transfemoral, transapical and transaortic approach. TAVI uses a catheter to replace the heart valve instead of the opening of the chest and completely removing the diseased valve. The TAVI valve is implanted within the diseased aortic valve. The valve is compressed onto the balloon that is expanded, pushing the leaflets of the diseased valve outside and when balloon deflated, the valve begins working instantly. This technique is still in its early stages but is growing rapidly through observational studies and randomized clinical trials.
The global TAVI market is expected to grow in future due to increasing ageing population, rising healthcare expenditure, increasing obese population, global economic development and increasing prevalence of inoperable aortic stenosis. Key trends in this market include rising demand for minimally invasive procedures, strong research and development efforts, rising mergers, technological advancements, favorable reimbursement policies, new product launch and TAVI for low-risk patients. However, the growth of this market will be hindered by stringent regulations, high cost of TAVI devices and high risks associated with the TAVI procedure.
The report “Global TAVI Market: Industry Analysis & Outlook (2018-2022)” analyses the development of this market, with focus on the U.S and European markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Edwards Lifesciences, Boston Scientific, Medtronic Plc. and Abbott Laboratories are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global TAVI market along with the study of the regional markets.
- 1. Market Overview
- 1.1 Aortic Stenosis
- 1.2 Transcatheter Aortic Valve Implantation (TAVI)
- 1.3 TAVI Procedure
- Table 1: Approaches to TAVI Procedure
- 1.4 Approaches to TAVI Procedure
- 1.5 Benefits and Risk Associated with TAVI Procedure
- 2. Global Market Analysis
- 2.1 Global TAVI Market by Value
- Table 2: Global TAVI Market by Value (2013-2017)
- 2.2 Global TAVI Market Forecast by Value
- Table 3: Global TAVI Market Forecast by Value (2018-2022)
- 2.3 Global TAVI Implant Volume
- Table 4: Global TAVI Implant Volume (2013-2017)
- 2.4 Global TAVI Implant Volume Forecast
- Table 5: Global TAVI Implant Volume Forecast (2018-2022)
- 2.5 Global TAVI Patient Population
- Table 6: Global TAVI Patient Population (2013-2017)
- 2.6 Global TAVI Patient Population Forecast
- Table 7: Global TAVI Patient Population Forecast (2018-2022)
- 2.7 TAVI Market by Region
- Table 8: TAVI Market by Region (2017)
- 3. Regional Market Analysis
- 3.1 The U.S.
- 3.1.1 The U.S. TAVI Market by Value
- Table 9: The U.S. TAVI Market by Value (2013-2017)
- 3.1.2 The U.S. TAVI Market Forecast by Value
- Table 10: The U.S. TAVI Market Forecast by Value (2018-2022)
- 3.1.3 The U.S. TAVI Implant Volume
- Table 11: The U.S. TAVI Implant Volume (2013-2017)
- 3.1.4 The U.S. TAVI Implant Volume Forecast
- Table 12: The U.S. TAVI Implant Volume Forecast (2018-2022)
- 3.1.5 The U.S. TAVI Implant Volume by Patient Type
- Table 13: The U.S. TAVI Implant Volume by Patient Type (2017)
- 3.1.6 The U.S. TAVI Implant Volume Forecast- Patient Type
- Table 14: The U.S. TAVI Implant Volume Forecast- Patient Type (2018-2022)
- 3.1.7 The U.S. TAVI Implant Volume by Access Route
- Table 15: The U.S. TAVI Implant Volume by Access Route (2017)
- 3.1.8 The U.S. Aortic Valve Disease Patient Population Forecast
- Table 16: The U.S. Aortic Valve Disease Patient Population Forecast (2017-2022)
- 3.2 Outside the U.S.
- 3.2.1 OUS TAVI Market by Value
- Table 17: OUS TAVI Market by Value (2013-2017)
- 3.2.2 OUS TAVI Market Forecast by Value
- Table 18: OUS TAVI Market Forecast by Value (2018-2022)
- 3.2.3 OUS TAVI Implant Volume
- Table 19: OUS TAVI Implant Volume (2013-2017)
- 3.2.4 OUS TAVI Implant Forecast by Volume
- Table 20: OUS TAVI Implant Forecast by Volume (2018-2022)
- 3.2.5 OUS TAVI Patient Population
- Table 21: OUS TAVI Patient Population (2013-2017)
- 3.2.6 OUS TAVI Patient Population Forecast
- Table 22: OUS TAVI Patient Population Forecast (2018-2022)
- 3.2.7 Europe TAVI Implant Volume by Patient Type
- Table 23: Europe TAVI Implant Volume by Patient Type (2017)
- 3.2.8 Europe TAVI Implant Volume Forecast by Patient Type
- Table 24: Europe TAVI Implant Volume Forecast by Patient Type (2018-2022)
- 3.2.9 Europe TAVI Implant Volume by Access Route
- Table 25: Europe TAVI Implant Volume by Access Route (2017)
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.1.1 Growing Ageing Population
- Table 26: Global Ageing Population (2013-2017)
- 4.1.2 Escalating Healthcare Spending
- Table 27: Global Healthcare Spending Per Capita (2013-2017)
- 4.1.3 Rising GDP Per Capita
- Table 28: Global GDP Per Capita (2013-2017)
- 4.1.4 Increase in Obese Population
- Table 29: Global Obese Population (2013-2017)
- 4.1.5 Increasing Prevalence of Inoperable Aortic Stenosis
- 4.2 Key Trends & Development
- 4.2.1 Strong Research & Development Efforts by Companies
- Table 30: R&D Expenditure of Companies (2017)
- 4.2.2 Rising Mergers and Acquisitions
- Table 31: Mergers and Acquisitions (2017)
- 4.2.3 Growing Adoption of Minimally Invasive Therapies
- 4.2.4 Recent Technological Advancements
- 4.2.5 Burden of Cardiovascular Diseases in the U.S.
- Table 32: Burden of Cardiovascular Diseases in the U.S. (2017)
- 4.2.6 Favorable Reimbursement Policies
- 4.2.7 TAVI for Low Risk Patients
- 4.2.8 New Product Launches
- 4.3 Challenges
- 4.3.1 Associated High Risk
- 4.3.2 Tough Regulatory Problems
- 4.3.3 High Cost Related to TAVI
- 5. Competition
- 5.1 Global Market
- 5.1.1 Revenue and Market Cap Comparison
- Table 33: Key Players - Revenue & Market Cap Comparison (2017)
- 5.1.2 Global TAVI Market Share by Company
- Table 34: Global TAVI Market Share by Company (2017/2022)
- 5.1.3 Global TAVI Market-Implanting Centers by Company
- Table 35: Global TAVI Market- Implanting Centers by Company (2017-2022)
- 5.1.4 Global TAVI Market- Total Implants by Company
- Table 36: Global TAVI Market- Total Implants by Company (2017-2022)
- 5.1.5 Global TAVI Market- Average Selling Price of Implants by Company
- Table 37: Global TAVI Market- Average Selling Price of Implants by Company (2017-2022)
- 5.2 The U.S.
- 5.2.1 The U.S. TAVI Market Share by Company
- Table 38: The U.S. TAVI Market Share by Company (2017/2022)
- 5.2.2 The U.S. TAVI Market-Implanting Centers by Company
- Table 39: The U.S. TAVI Market-Implanting Centers by Company (2017-2022)
- 5.2.3 The U.S. TAVI Market-Total Implants by Company
- Table 40: The U.S. TAVI Market-Total Implants by Company (2017-2022)
- 5.2.4 The U.S. TAVI Market-Average Selling Price of Implants by Company
- Table 41: The U.S. TAVI Market-Average Selling Price of Implants by Company (2017-2022)
- 5.3 Outside the U.S.
- 5.3.1 OUS TAVI Market Share by Company
- Table 42: OUS TAVI Market Share by Company (2017/2022)
- 5.3.2 OUS TAVI Market-Implanting Centers by Company
- Table 43: OUS TAVI Market-Implanting Centers by Company (2017-2022)
- 5.3.3 OUS TAVI Market-Total Implants by Company
- Table 44: OUS TAVI Market-Total Implants by Company (2017-2022)
- 5.3.4 OUS TAVI Market-Average Selling Price of Implants by Company
- Table 45: OUS TAVI Market-Average Selling Price of Implants by Company (2017-2022)
- 6. Company Profiles
- 6.1 Edwards Lifesciences
- 6.1.1 Business Overview
- Table 46: Edwards Lifesciences Corporation Revenue by Segments (2017)
- 6.1.2 Financial Overview
- Table 47: Edwards Lifesciences Net Sales and Net Income (2013-2017)
- 6.1.3 Business Strategies
- Table 48: Edwards Lifesciences R&D Expenditure (2015-2017)
- 6.2 Medtronic Plc.
- 6.2.1 Business Overview
- Table 49: Medtronic Plc. Revenue by Segments (2017*)
- 6.2.2 Financial Overview
- Table 50: Medtronic Plc. Net Sales and Net Income (2013-2017*)
- 6.2.3 Business Strategies
- 6.3 Boston Scientific
- 6.3.1 Business Overview
- Table 51: Boston Scientific Revenue by Segments (2017)
- 6.3.2 Financial Overview
- Table 52: Boston Scientific Revenue and Net Income (2013-2017)
- 6.3.3 Business Strategies
- Table 53: Boston Scientific R&D Expenditure (2015-2017)
- 6.4 Abbott Laboratories
- 6.4.1 Business Overview
- Table 54: Abbott Laboratories Revenue by Segments (2017)
- 6.4.2 Financial Overview
- Table 55: Abbott Laboratories Net Sales and Net Earnings (2013-2017)
- 6.4.3 Business Strategies
- Table 56: Abbott Laboratories R&D Expenditure (2015-2017)